

# Câncer de Próstata

## **Flutamida + Leuprorrelina**

Flutamida: 250mg VO TID

Leuprorrelina: 7,5mg IM a cada 28 dias ou 22,5 mg IM a cada 12 semanas

Ref. (01)

## **Flutamida + Gosserrelina**

Flutamida: 250 mg VO TID

Gosserrelina: 10,8 mg SC a cada 12 semanas

Ref. (02)

## **Docetaxel + Prednisona**

Docetaxel: 75 mg/m<sup>2</sup> IV D1

Prednisona: 5 mg VO BID

a cada 21 dias no total de 10 ciclos

Ref. (03)

## **Docetaxel + Estramustina**

Docetaxel: 35 mg/m<sup>2</sup> IV D2 das semanas 1 e 2

Estramustina: 420 mg VO nas primeiras 4 doses e 280 mg VO nas próximas 5 doses D1 ao D3 das semanas 1 e 2

a cada 21 dias

Ref. (04)

## **Mitoxantrona + Prednisona**

Mitoxantrona: 12 mg/m<sup>2</sup> IV D1

Prednisona: 5 mg VO BID

a cada 21 dias

Ref. (05)

## **Docetaxel**

Docetaxel: 20-40 mg/m<sup>2</sup> semanalmente por 3 semanas

a cada 4 semanas

Ref. (06)

## **Gosserrelina**

Gosserrelina: 3,6 mg SC D1

a cada 28 dias

## OU

Gosserrelina: 10,8 mg SC D1  
a cada 12 semanas

Ref. (07)

### **Leuprorrelina**

Leuprorrelina: 7,5 mg IM D1  
a cada 28 dias

## OU

Leuprorrelina: 22,5 mg IM D1  
a cada 12 semanas

Ref. (08)

### **Bicalutamida**

Bicalutamida: 50 mg VO diariamente

Ref. (09)

### **Flutamida**

Flutamida: 250 mg VO TID

Ref. (10)

### **Nilutamida**

Nilutamida: 300 mg VO do D1 ao D30, e então 150 mg VO  
diariamente

Ref. (11)

### **Prednisona**

Prednisona: 5 mg VO BID

Ref. (12)

### **Cetoconazol**

Cetoconazol: 1200 mg VO diariamente

Ref. (13)

### **Paclitaxel**

Paclitaxel: 135-170 mg/m<sup>2</sup> IV em 24 horas D1  
a cada 21 dias

Ref. (14)

## OU

Paclitaxel: 150 mg/m<sup>2</sup> IV D1 em infusão de 1 hora a cada 6 semanas.

a cada 8 semanas Ref. (15)

## **DES**

Dietilestilbestrol: 1 a 3 mg VO no dia Ref. (16)

## **Cabazitaxel + Prednisona**

Cabazitaxel: 25 mg/ m<sup>2</sup> IV a cada 21 dias

Prednisona: 10 mg VO/dia Ref. (17)

## **Vinorelbina + Hidrocortisona**

Vinorelbina: 30 mg/ m<sup>2</sup> Dias 1 e 8 a cada 21 dias.

+

Hidrocortisona: 40 mg VO dia, uso contínuo. Ref. (18)

## **Abiraterona + Prednisona**

Abiraterona: 1g VO dia

+

Prednisona: 5 mg VO 2 x dia, uso contínuo. Ref. (19)

1. Eisenberger MA, *et al.* Prognostic factors in stage D2 prostate cancer: important implications for future trials; results of a cooperative intergroup study (INT.0036). The national cancer institute intergroup study #0036. *Semin oncol* 1994;21:613-619.
2. Jurincic CD, *et al.* Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study. *Semin oncol* 1991;18 (Suppl 6):21-25.
3. Tannock IF, de Wit R, Berry WR, *et al.*: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 351:1502-1512, 2004.
4. Copur MS, *et al.* Weekly docetaxel and estramustine in patients

- with hormone-refractory prostate cancer. *Semin oncol* 2001;28:16-21.
5. Tannock IF, *et al.* Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J clin oncol* 1996;14:1756-1764.
  6. Dreicer R. Chemotherapy for advanced prostate cancer: docetaxel and beyond. *Hematol oncol clin north Am* 2006;20:935-926.
  7. Dijkman GA, *et al.* A randomized trial comparing the safety and efficacy of the zoladex 10.8mg depot, administered every twelve weeks, to that of the zoladex 3.6mg depot, administered every four weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. *Eur Urol* 1995;27:43-46.
  8. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. *N Engl J Med* 1984;311:1281-1286.  
Sharifi R, *et al.* Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. *Clin Ther* 1996;18:647-657.
  9. Schellhammer PF, *et al.* Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double blind, randomized, multicenter trial. *Urology* 1997;50:330-336.
  10. McLeod DG, *et al.* The use of flutamide in hormone refractory metastatic prostate cancer. *Cancer* 1993;72:3870-3873.
  11. Janknegt RA, *et al.* Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. *J Urol* 1993;149:77-82.
  12. Tannock IF, *et al.* Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-

resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996;14:1756-1764.

13. Johnson DE, *et al.* Ketoconazole therapy for hormonally refractive metastatic prostate cancer *Erology* 1988;31:132-134.
14. Roth BJ. *et al.* Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group *cancer* 1993;2:245-2260.
15. Ahmed S, *et al.* Feasibility of weekly one hour paclitaxel in hormone refractory prostate cancer (HRPC): a preliminary report of a phase II trial. *Proc Am Soc Clin Oncol* 1998; 17:325a.
16. Smith DC, Redman BG, Flaherty LE, Li L, *et al.* phase II trial of oral diethylstilbesterol as a secondline hormonal agent in advanced prostate cancer. *Urology*.1998;52:257-60.
17. Bono J. S. de, Oudard S, Ozguroglu M, *et al.* Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). *J Clin Oncol*. 2010. 28:15s (suppl; abstr 4508).
18. Abratt R. P, Brune D., Dimopoulos M. - A, *et. Al.* Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. *Ann Oncol*. 2004;15(11): 1613-1621.
19. de Bono JS, Logothetis CJ, Molina A, *et. al.* Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med*. 2011; 26;364(21):1995-2005.